Honghao Fang
Education
M.Sc., global health science and epidemiology, University of Oxford; B.Sc., health, health care administration, and management, Fudan University
Summary of Experience
Ms. Fang is a health economist who specializes in generating evidence from health economics and outcomes research (HEOR). She conducts research to assess clinical, economic, and humanistic burdens of various diseases and to compare clinical effectiveness, safety, and economic values across different treatments. Ms. Fang has expertise in economic modeling, including cost-effectiveness and budget impact analysis, as well as conducting patient and physician surveys, chart reviews, real-world database analyses, and systematic literature reviews. She has worked across a variety of disease areas, including oncology, hematology, dermatology, immunology, infectious diseases, mental health disorders, and rare diseases. Ms. Fang’s research has supported assessments of market access and value propositions – including health technology assessment (HTA) submissions – in North America, Asia, the UK, and Europe. Her research has also been published in several peer-reviewed journals and presented at international conferences.
-
The Economic Impact of Treatment Sequences for Chronic Lymphocytic Leukemia in the United States: A Cost of Care and Budget Impact Model of Venetoclax Plus Obinutuzumab Sequences
Journal of Clinical Pathways, 2022
2022Davids MS, Manzoor BS, Hazra NC, Fang H, Ravelo A, Han F, Guerin A, Sail K, Shapouri S, Shadman M
-
Cost-effectiveness analysis of double low-dose budesonide and low-dose budesonide plus montelukast among pediatric patients with persistent asthma receiving Step 3 treatment in China
Journal of Medical Economics, 2020
2020Wang X, Fang H, Shen K, Liu T, Xie J, Liu Y, Wu P, Chen Y, Zhong J, Wu E, Zhou W, Wu B
-
The cost-effectiveness of low-dose budesonide as a Step 2 treatment for pediatric asthma in China
Journal of Comparative Effectiveness Research, 2020
2020Wang X, Fang H, Shen K, Liu T, Xie J, Liu Y, Zhong J, Wu E, Zhou W, Wu B
-
Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A
Journal of Managed Care & Specialty Pharmacy, 2020
2020Zhou ZY, Raimundo K, Patel A, Han S, Ji Y, Fang H, Zhong J, Betts K, Mahajerin A